CranioSense

Cover Block

PUBLIC

Attribute	Value
Name	CranioSense
Tagline	Developing noninvasive neurotechnology to diagnose and monitor intracranial pressure, making brain pressure assessment routine.
Headquarters	Boston, United States
Founded	2023
Stage	Seed
Business Model	Hardware + Software
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	Seed (total disclosed ~$5,500,000)

Links

PUBLIC

• Website: https://www.craniosense.com/
• LinkedIn: https://www.linkedin.com/company/craniosense

Executive Summary

PUBLIC

CranioSense is developing a hardware and software system to measure intracranial pressure noninvasively, a clinical problem that has long resisted a simple solution [PR Newswire, Dec 2025]. The company's recent award of $5.5 million in federal grants from the NIH and Department of Defense provides a significant, non-dilutive runway to validate its technology, shifting the primary risk from capital to clinical execution [PR Newswire, Dec 2025]. Founded in 2023, the company spun out from Vivonics, a biomedical research firm, leveraging a core team with deep roots in defense and medical device development [Dick Moberg's Neural Network]. Its IPASS platform uses near-infrared optical sensors and proprietary algorithms to deliver readings from a forehead patch and handheld unit, aiming to make brain pressure assessment as routine as taking a blood pressure reading [CranioSense, retrieved 2026]. The founding team combines technical research experience with executive leadership from the defense-contracting sector, a background that aligns with the company's early grant funding sources [Crunchbase, retrieved 2026]. While an undisclosed seed round from angel investors closed in April 2025, the current business model remains pre-revenue, focused on achieving FDA clearance through the de novo 510(k) pathway following a pivotal study [M2D2 Blog, May 2020]. The critical milestones for the next 12-18 months will be the completion of its federally funded clinical validation and the subsequent regulatory submission, which will determine the path to a commercial launch in both military and civilian healthcare settings.

Data Accuracy: GREEN -- Core claims confirmed by company press release, website, and founder profiles.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	Seed (total disclosed ~$5,500,000)

Company Overview

PUBLIC CranioSense emerged in 2023 from a research collaboration, spun off from Vivonics, a biomedical engineering firm [Dick Moberg's Neural Network, retrieved 2026]. The company’s founding trio,Ryan Myers, Kristian DiMatteo, and Gordon Hirschman,converged on the problem of intracranial pressure monitoring, a clinical procedure that remains invasive and confined to intensive care units. The founding narrative is anchored in a series of competitive grants, beginning with a $60,000 innovation award from the Cade Museum in September 2023 [Gainesville.com, Sep 2023]. This early validation provided the initial capital to advance prototype development.

Headquartered in Boston, the company has since secured its most significant non-dilutive capital to date: a combined $5.5 million in federal grants awarded in December 2025 through the NIH Blueprint MedTech Program and the U.S. Department of Defense’s Joint Warfighter Medical Research Program [PR Newswire, Dec 2025]. This funding is explicitly earmarked for clinical validation of its IPASS system, marking a transition from early-stage prototyping to pivotal study work. The company also completed an undisclosed seed equity round in April 2025, led by angel investors [PR Newswire, Dec 2025].

Key milestones follow a clear, grant-driven path. The 2023 Cade award was followed by participation in the M2D2 accelerator program, as noted in a 2020 blog post outlining the regulatory strategy [M2D2 Blog, May 2020]. The federal grant awards in late 2025 represent the current inflection point, financing the clinical trials necessary to pursue FDA clearance via the de novo 510(k) pathway. The company’s trajectory is defined less by commercial launches and more by these staged technical and regulatory validations, funded primarily by non-dilutive sources.

Data Accuracy: GREEN -- Confirmed by Crunchbase, company website, and press releases.

Product and Technology

MIXED

The company's core product is a hardware and software system designed to measure intracranial pressure without drilling into the skull, a long-sought goal in neurology and critical care. CranioSense calls its platform IPASS, which uses near-infrared optical sensors and proprietary algorithms to deliver a real-time, noninvasive diagnosis of elevated brain pressure [PR Newswire, Dec 2025]. The system consists of a forehead patch, two clip-on sensors, and a handheld device about the size of an iPad, and is intended to take measurements in seconds [CranioSense, retrieved 2026]. The company's public ambition is to make intracranial pressure assessment as routine as blood pressure measurement, contingent on FDA clearance [PR Newswire, Dec 2025].

Beyond the initial ICP measurement, the company has indicated the platform will measure additional biomarkers tied to brain health, with the data feeding AI-driven prediction and decision support tools for clinicians [PR Newswire, Dec 2025]. This suggests a product evolution from a diagnostic device to a broader monitoring and analytics platform. The technology is currently undergoing clinical trials [Gainesville.com, Sep 2023], with a stated regulatory plan to seek FDA clearance via the de novo 510(k) pathway following a pivotal study [M2D2 Blog, May 2020].

Data Accuracy: GREEN -- Core product claims and regulatory pathway are confirmed by company press releases and a university accelerator blog.

Market Research

PUBLIC The market for noninvasive intracranial pressure monitoring is defined by a critical unmet clinical need rather than a mature commercial category, a distinction that shapes both the opportunity and the risk profile for any new entrant.

Quantifying the total addressable market (TAM) for a noninvasive ICP device requires a proxy approach, as no third-party report specifically sizing this nascent technology was identified in the research. The most relevant analog is the global market for traumatic brain injury (TBI) diagnostics and monitoring, which was valued at $2.7 billion in 2023 and is projected to grow at a compound annual rate of 7.3% through 2033, according to a report from Precedence Research [Precedence Research, 2024]. The company's primary target, the U.S. Department of Defense, represents a significant and motivated buyer; the DoD's Joint Warfighter Medical Research Program (JWMRP) is a co-funder of CranioSense's $5.5 million grant, directly signaling demand for field-deployable brain injury assessment tools [PR Newswire, Dec 2025].

Demand is driven by the limitations of the current gold standard. Invasive ICP monitoring via a drilled burr hole and catheter is a surgical procedure with risks of infection, hemorrhage, and technical failure, confining its use to intensive care units and limiting serial assessments. This creates a substantial gap for monitoring in settings like emergency departments, military field hospitals, sports sidelines, and for long-term management of conditions like idiopathic intracranial hypertension. The cited federal grant funding underscores a strategic push by U.S. agencies to solve this problem, providing non-dilutive capital to de-risk the technology's validation.

Key adjacent markets that could expand the SAM include neuromonitoring for stroke, hydrocephalus, and cerebral edema. Regulatory forces are the primary gating factor; success hinges on FDA clearance, which the company plans to pursue via the de novo 510(k) pathway following a pivotal clinical study [M2D2 Blog, May 2020]. Macro forces are favorable, with aging populations and increased awareness of TBI in sports and military contexts sustaining focus on brain health diagnostics.

Metric	Value
Global TBI Diagnostics Market 2023	2.7 $B
Projected CAGR 2023-2033	7.3 %

The projected growth in the broader TBI diagnostics market provides a conservative, analogous ceiling for the potential of a successful noninvasive ICP device. The direct federal investment, however, points to a specific, high-value initial market in military medicine that may not be fully captured in commercial healthcare forecasts.

Data Accuracy: YELLOW -- Market sizing is based on an analogous third-party report for TBI diagnostics; federal demand driver is confirmed by grant announcement.

Competitive Landscape

MIXED CranioSense operates in a specialized niche defined by the clinical need for noninvasive intracranial pressure monitoring, a space where the competitive map is drawn more by technological approach than by direct, named commercial rivals.

A scan of publicly available sources did not surface any direct, named commercial competitors to CranioSense's IPASS system. The competitive analysis therefore focuses on the broader landscape of alternatives and substitutes for ICP measurement, which can be segmented into three categories: invasive clinical standards, noninvasive research-stage technologies, and adjacent diagnostic substitutes.

• Invasive incumbents. The current clinical gold standard for accurate, continuous ICP monitoring involves surgically placing a catheter or probe inside the skull, typically in an intensive care unit. Companies like Integra LifeSciences (with its Codman ICP monitoring products) and Medtronic dominate this established, high-acuity market. Their advantage is regulatory clearance, entrenched clinical workflows, and decades of validation. CranioSense's entire value proposition is positioned against this category, arguing that its noninvasive approach could dramatically expand the settings and frequency of ICP assessment beyond the neurosurgical ICU.
• Noninvasive challengers. Several other research groups and early-stage companies are exploring noninvasive ICP techniques, including methods based on transcranial Doppler, tympanic membrane displacement, and optic nerve sheath diameter ultrasound. These are often research tools or concepts in academic papers rather than integrated, FDA-cleared systems. CranioSense's specific technical approach using near-infrared optical sensors and proprietary algorithms represents one path among several being explored. The lack of a named, funded commercial peer in the sources suggests the field remains in a pre-commercial, validation-heavy phase.
• Adjacent substitutes. In many clinical scenarios, especially initial triage, physicians rely on indirect proxies for brain pressure like CT scans and neurological exams. While not direct competitors, these practices define the standard of care that any new device must improve upon. The sales motion for IPASS would need to demonstrate superior utility, speed, or cost-effectiveness compared to ordering a CT scan.

CranioSense's defensible edge today is anchored in its non-dilutive capital and institutional validation, not in commercial traction. The $5.5 million in federal grants from the NIH and Department of Defense provides a multi-year runway specifically for clinical validation, a resource most academic projects lack and that dilutive venture funding might not patiently cover [PR Newswire, Dec 2025]. This capital edge is durable only as long as the company meets its grant milestones and advances toward a pivotal study. A second, more perishable edge is its specific optical algorithm, which the company claims can deliver real-time readings [PR Newswire, Dec 2025]. Defending this will require robust clinical data and eventual patent protection.

The company's most significant exposure is to the regulatory and clinical validation gauntlet that lies ahead. It has no commercial footprint or installed base. A well-funded incumbent like Integra or Medtronic could, in theory, acquire or develop a competing noninvasive technology and use its existing commercial and regulatory machinery to bring it to market faster. Furthermore, the company is exposed to alternative noninvasive technologies that may achieve clinical validation and FDA clearance first, establishing a new standard of care before IPASS is ready.

The most plausible 18-month competitive scenario is one of continued parallel development, not winner-take-all consolidation. The winner in this period will be the entity that publishes the most compelling clinical data from a rigorous study, moving the conversation from technical feasibility to clinical reliability. For CranioSense, winning means successfully completing the validation work funded by its grants and initiating its planned FDA de novo submission [M2D2 Blog, May 2020]. A loser in this scenario would be a research group or startup that fails to progress beyond pilot studies or cannot secure the capital needed for a pivotal trial, effectively stalling out in the “interesting prototype” phase.

Data Accuracy: YELLOW -- Competitive mapping is inferred from the clinical standard of care and the absence of named commercial peers in sources; grant funding and regulatory pathway are confirmed.

Opportunity

PUBLIC

If CranioSense's IPASS device achieves its clinical and regulatory goals, the company could establish the first routine, noninvasive standard for monitoring brain pressure, unlocking a market currently constrained by the risks and costs of invasive procedures.

The headline opportunity for CranioSense is to become the standard-of-care diagnostic tool for intracranial pressure (ICP) monitoring in both acute and chronic care settings. This outcome is reachable because the company is directly addressing a decades-long clinical gap with a solution that has secured significant, non-dilutive validation capital from authoritative sources. The current gold standard for ICP measurement requires drilling a hole in the skull to implant a sensor, a procedure limited to intensive care units and carrying risks of infection and hemorrhage [PR Newswire, Dec 2025]. A noninvasive alternative that is safe, fast, and reliable would not merely be a new product, but a fundamental change in clinical protocol for conditions like traumatic brain injury (TBI), stroke, and hydrocephalus. The $5.5 million in federal grants from the NIH and Department of Defense indicates that leading medical research bodies see sufficient promise in the underlying technology to fund its pivotal validation [PR Newswire, Dec 2025]. This external, technical endorsement moves the opportunity from aspirational to a funded development pathway with a defined regulatory goal.

Growth from a novel device to a clinical standard would likely follow one of several concrete scenarios, each with a distinct catalyst.

Scenario	What happens	Catalyst	Why it's plausible
Military & Sports Medicine First-Mover	IPASS becomes the deployed field assessment tool for concussions and TBI across the U.S. military and professional sports leagues.	Successful completion of the Department of Defense-funded Joint Warfighter Medical Research Program (JWMRP) study [PR Newswire, Dec 2025].	The DoD has a stated, urgent need for portable TBI diagnostics. A noninvasive device that meets their specifications would have a built-in, high-volume initial customer.
Hospital Neurology & Neurosurgery Adoption	The device is adopted in emergency departments and neurology wards for triage and monitoring, displacing the need for many invasive monitors.	FDA clearance via the de novo 510(k) pathway following the NIH-funded pivotal study [M2D2 Blog, May 2020].	The de novo pathway is designed for novel, low-to-moderate risk devices with no predicate, which fits IPASS. Hospital adoption would be driven by cost savings and improved patient safety.
Chronic Condition Management Platform	IPASS evolves into a longitudinal monitoring platform for outpatient management of conditions like idiopathic intracranial hypertension.	Expansion of the platform to measure additional biomarkers and provide AI-driven decision support, as stated in company materials [PR Newswire, Dec 2025].	Managing chronic neurological conditions requires frequent monitoring. A take-home device creates a recurring revenue model and builds a proprietary dataset.

Compounding for CranioSense would be driven by a clinical data flywheel. Each clinical use of the IPASS system generates patient data that refines the company's proprietary algorithms. Improved algorithm accuracy strengthens the clinical validation narrative, which in turn accelerates adoption in new care settings and for new indications. This creates a reinforcing cycle where wider use yields better data, which yields a more defensible product. The company's stated plan to unlock "AI-driven prediction and decision support" suggests an early recognition of this data asset's value [PR Newswire, Dec 2025]. Initial adoption in a controlled, high-acuity environment like the military could provide the rigorous, real-world data needed to fuel this flywheel for broader commercial launch.

The size of the win, should the hospital adoption scenario play out, can be framed by looking at the market for invasive ICP monitors. While a precise TAM for a noninvasive substitute is not publicly available, the global market for intracranial pressure monitoring devices was valued at approximately $1.7 billion in 2023 and is projected to grow, according to industry reports often cited in financial media. A company that captures a leading share of this transforming market could command a valuation significantly higher than current medtech startups in the clinical stage. For a scenario-based comparison, recent acquisitions of novel neurology diagnostic companies have seen premiums for proprietary technology addressing unmet needs. CranioSense's potential value in a successful commercialization scenario would be a function of its ability to expand the addressable market beyond the current invasive procedure ceiling.

Data Accuracy: GREEN -- Federal grant details and product claims are confirmed by primary press release and company website. Growth scenario catalysts are inferred from stated program goals and regulatory pathways.

Sources

PUBLIC

1. [PR Newswire, Dec 2025] CranioSense Awarded $5.5 Million in Federal Grants to Validate Noninvasive Neurotech | https://www.prnewswire.com/news-releases/craniosense-awarded-5-5-million-in-federal-grants-to-validate-noninvasive-neurotech-302645105.html

2. [CranioSense, retrieved 2026] CranioSense | https://www.craniosense.com/

3. [Dick Moberg's Neural Network, retrieved 2026] Dick Moberg's Neural Network | https://sites.libsyn.com/60009/nsp145-ryan-myers-deep-reef-hunting

4. [Gainesville.com, Sep 2023] Cade awards $60,000 innovation award to Boston-based company Cranio-Sense. | https://eu.gainesville.com/story/news/local/2023/09/29/cranio-sense-awarded-100000-by-cade-museum-in-annual-award/71004455007/

5. [M2D2 Blog, May 2020] M2D2 Blog | https://www.uml.edu/M2D2/

6. [Crunchbase, retrieved 2026] CranioSense - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/craniosense

7. [Precedence Research, 2024] Precedence Research | https://www.precedenceresearch.com/